Background {#Sec1}
==========

The epigenome is believed to have significant plasticity throughout life and is likely influenced by a variety of factors including diet, inflammation, physical activity, smoking, and aging \[[@CR1], [@CR2]\]. DNA (deoxyribonucleic acid) methylation at CpG (5′---C---phosphate---G---3′) sites (DNA regions where a guanine nucleotide follows a cytosine) is the most commonly studied epigenetic feature in human populations. DNA methylation patterns are known to be tissue specific, although some CpGs show similar methylation levels across tissues \[[@CR3]--[@CR6]\]. Methylation patterns of DNA extracted from blood have been associated with gender \[[@CR7]--[@CR9]\], aging \[[@CR10]--[@CR18]\], embryonic growth restriction \[[@CR19]\], and many age-related diseases, such as cancer and diabetes \[[@CR20]--[@CR23]\]. Additionally, variation in DNA methylation has been suggested to explain disease phenotype differences between monozygotic twins \[[@CR24]--[@CR27]\] and associations between in utero environment and diseases during adult life \[[@CR28], [@CR29]\]. Mechanistically, variation in DNA methylation likely reflects variation in histone modifications, chromatin conformation, and gene expression \[[@CR30]\], with hypo-methylation of the promoter region and hyper-methylation of the gene body often reflecting increased expression \[[@CR31]\].

Alterations in DNA methylation that occur as humans age have been described \[[@CR10], [@CR11], [@CR14], [@CR32]--[@CR35]\]. Analysis of genome-wide DNA methylation in blood cells has demonstrated that 15--30% of CpG sites are associated with age \[[@CR36]--[@CR38]\]. In addition, DNA methylation has been used as a measure of "epigenetic aging" (i.e., epigenetic clock) and to investigate potential environmental factors that affect biological aging \[[@CR38]--[@CR41]\]. An accelerated epigenetic clock has been associated with higher mortality risk, as well as reduced cognitive and physical health \[[@CR42], [@CR43]\].

Prior studies have conducted genome-wide searches for age-associated CpG sites in humans. Most have been conducted using data from individuals of European ancestry, and none have done so in a sex-specific manner \[[@CR44]\]. In this study, we used genome-wide methylation data on 189 males and 211 females from Bangladesh to identify age-associated CpG sites in a sex-specific manner and characterize these CpG sites with respect to genomic context. We chose to conduct a stratified analysis as there are many biological differences between males and females that may impact how the epigenome changes with age. Understanding how methylation changes with age is critical for understanding biological processes associated with human aging and the role of epigenetics in susceptibility to aging-related diseases.

Methods {#Sec2}
=======

Study sample {#Sec3}
------------

The Bangladesh Vitamin E and Selenium Trial (BEST) is a 2 × 2 factorial randomized chemoprevention trial evaluating the long-term effects of vitamin E and selenium supplementation on non-melanoma skin cancer risk and has been described in detail elsewhere \[[@CR45]\]. Participants were eligible for BEST if they resided in select rural communities in central Bangladesh, were between ages 25 and 65 years old, had arsenic-induced skin lesions, and no prior cancer history. Between April 2006 and August 2009, a total of 7000 individuals were enrolled. In-person interviews, clinical evaluations, and urine and blood sample collection were performed by trained study physicians, blinded to participants' arsenic exposure using structured protocols. For the present study, 413 participants with baseline specimens collected prior to the intervention were randomly sampled.

The study protocol was approved by the relevant institutional review boards in the United States (The University of Chicago and Columbia University) and Bangladesh (Bangladesh Medical Research Council). Informed consent was provided by participants prior to the original BEST study.

Measurement of methylation {#Sec4}
--------------------------

Details on methylation measurement in this population have been given in detail elsewhere \[[@CR46]\]. Briefly, DNA was extracted using DNeasy Blood kits (Qiagen, Valencia, CA, USA), and bisulfite conversion was performed using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA, USA). DNA methylation was measured in 500 ng of bisulfite-converted DNA per sample using the Illumina HumanMethylation 450 K (485,577 CpG sites) BeadChip kit (Illumina, San Diego, CA, USA) according to the manufacturer's protocol. The average methylation at each CpG site is represented as a continuous score (β value) between 0 (unmethylated) and 1 (completely methylated). From the 413 participants, we excluded 6 samples for inconsistency between self-reported and methylation-derived sex, and 7 samples with \> 5% of CpGs either having p for detection \> 0.05 or missing values. This resulted in 400 samples used for analyses (189 males and 211 females). We excluded 416 probes on the Y chromosome, probes lacking chromosome data (mostly control probes; *n* = 65), probes mapping to multiple locations (*n* = 41,937), probes with target CpG sites containing SNPs (*n* = 20,869), and probes with \> 10% missing data across samples (*n* = 1932). This resulted in a total of 423,188 probes included in this analysis. Based on 11 samples run in duplicate across two different plates, the average inter-assay Spearman correlation coefficient was 0.987 (range, 0.974--0.993).

Measurement of gene expression {#Sec5}
------------------------------

Sample processing for gene expression analysis has been described previously in detail \[[@CR46]\]. Briefly, RNA (ribonucleic acid) was extracted from stored Mononuclear cells using RNeasy Micro Kit from QIAGEN (Valencia, CA, USA). Nanodrop 1000 spectro-photometer (Thermo Scientific, Wilmington, DE, USA) was used to check RNA concentration and quality and the Illumina TotalPrep 96 RNA Amplification kit was used for cDNA synthesis. The Illumina HumanHT-12-v4 BeadChip (47,231 probes covering 31,335 genes) was used to measure transcript abundance according to manufacturer's protocol.

Statistical analysis {#Sec6}
--------------------

For each CpG site, a sex-stratified linear regression model was used to assess the association between age in years (independent variable) and the logit-transformed methylation β value (ratio of methylated to unmethylated alleles; dependent variable). Coefficients and standard errors (SEs) from the regression models correspond to a 1-year age increase. To increase our chances of finding truly significant results and account for multiple testing in both sex-specific models, we use a significance threshold (*p* \< 5 × 10^− 8^) slightly more stringent than the Bonferroni-corrected value (*p* \< 6 × 10^− 8^ = 0.05/(423,188\*2)). For differentially methylated probes with *p* \< 5 × 10^− 8^, we used sex-stratified linear regressions to examine the association of methylation with corresponding RNA transcript levels of the gene assigned to the methylation locus (based on Illumina's annotation file). To control for the potential confounder, cell type composition, we used the RefFreeEWAS method \[[@CR47]\]. In a separate analysis, we used the reference-based method, MethylSpectrum \[[@CR48]\], a reference-based adjustment for blood cell type, but the resulting volcano plot (not shown) was asymmetric toward hyper-methylation of sites; potentially representing the effects of unmeasured confounding. Therefore, we present results from the analysis using the RefFreeEWAS method. This method empirically establishes the top *d* number (user setting; we used d = 5) of latent variables for which to adjust. An additional covariate in our models adjusted for batch (or plating) effect. For the enrichment analyses, we used a Fisher exact test to determine if a higher proportion of significant (*p* \< 0.05) CpGs were found in a specific genomic region compared to all analyzed CpGs. We conducted a second set of tests to compare the number of significant CpGs found within a specific genome region between male and female to see if there was a difference by sex. Among the top 100 CpGs within each sex, we used a linear regression model with logit-transformed CpG beta values and cell type composition matrix (set of 6 blood cell type variables estimated using methyl spectrum) as the independent variables and the expression levels for the Illumina assigned gene as the dependent variable to identify significant methylation-expression associations. For those CpG-gene expression sets found to have a significant association, we reran the regression model with an additional age and age-CpG interaction term. A Bonferroni corrected *p* (males: 0.05/417 and females: 0.05/538) was considered to be statistically significant. We used the R Statistical package v3.2.5 \[[@CR49]\] to run all analyses.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

Comparing participant characteristics by sex (Table [1](#Tab1){ref-type="table"}), we observed significant differences among most variables. On average, males had a higher proportion who smoked and a higher proportion of T-helper (CD4T) cells. A lower proportion of males compared to females had high urinary arsenic levels and had a lower proportion of circulating natural killer (NK), monocytes (Mono), and granulocytes (Gran) cells. The mean age was 43.1 (standard deviation (SD) = 9.1) for males and 44.3 (SD = 11.1) for females and there was a significant difference in the age distribution between sexes (Additional file [1](#MOESM1){ref-type="media"}). Table 1Characteristics of study participants, by sexMales (*N* = 189)Females (*N* = 211)N%N%*P* value\*Age0.0099\* \<353619.05023.7 ≥35-\<456132.35325.1 ≥45-\<556735.45727.0 ≥552513.25124.2BMI0.2527\* \<18.56534.48741.2 ≥18.5-\<24.59952.410650.2 ≥24.52513.2188.5Smoking\< 0.0001\* Never73.710248.3 Ever18296.310951.7Urinary Total Arsenic Concentration (μg/g)0.0004\* \<156232.83617.1 ≥15 - \< 37.54825.45425.6 ≥37.5 - \< 104.24624.35425.6 ≥104.23317.56731.8meanrangemeanrange*P* value\*Average Blood Cell Percentages (estimated by MethylSpectrum) CD8T0.220.07--0.380.20.05--0.420.0437\* CD4T0.070--0.250.050--0.230.0016\* NK0.020--0.090.030--0.09\< 0.0001\* Bcell0.080.03--0.200.080.02--0.150.8230\* Mono0.070--0.140.080--0.150.0046\* Gran0.480.34--0.630.490.31--0.700.0909\**Abreviations*: *N* Number, % Percent\*Chi-squared test used for categorical variable and t-test used for continuous variables

Sex-specific age-associated CpG sites {#Sec9}
-------------------------------------

At *p* threshold of 5 × 10^− 8^, we observed 3479 CpG sites at which methylation was associated with age among women and 986 among men (Fig. [1](#Fig1){ref-type="fig"}). Focusing only on these significant sites, there is some overlap between the sexes (530 in common between women and men significant sets). However, among the 3479 age-associated methylation sites among women, 3048 (87.6%) are age-associated methylation sites among men at a *p* \< 0.05 and likewise, among the 986 age-associated methylation sites among men, 946 (95.9%) are age-associated methylation sites among women at a *p* \< 0.05. The 50 most significant CpGs for each sex are reported in Additional file [2](#MOESM2){ref-type="media"} with 32 age-associated CpGs in common among the top 100 male and female RefFreeEWAS results (Additional file [3](#MOESM3){ref-type="media"}). Additional file [4](#MOESM4){ref-type="media"} shows a comparison between several RefFreeEWAS models some of which are sex-specific and some adjust for smoking. Interestingly, the overlap in top 100 CpGs when comparing male only to female only models is 31; while the same comparison for models that adjust for smoking produces only 28 overlapping CpGs. Fig. 1Manhattan plot showing the association between age and CpG sites for 211 women (top) and 189 men (bottom). Horizontal black line indicates *p* =5 × 10^− 8^

We used an independent validation set consisting of 400 Bangladeshi individuals (167 males) participating in the Health Effects of Arsenic Longitudinal Study (HEALS) \[[@CR50]\] to assess overlap of significant age-associated CpGs identified in this current study. In this sample 90% of females reported never smoking compared with 74% of males reporting ever smoked. The mean age was 41.1 (SD = 10.1) for males and 34.4 (SD = 8.8) for females with a significant difference in the age distribution between sexes (Additional file [5](#MOESM5){ref-type="media"}). For BEST the 450 K (CpGs) Illumina chip was used while the EPIC array (\~ 850 K CpGs) was used in HEALS. Because 47,780/423604 (11.3%) CpGs where not present on the 850 K chip, we were unable to validate observed significant results for 93/986 (9.4%) CpGs among males, 301/3479 (8.7%) among females, and 9/100 (9%) of the top 100 CpGs among both sexes. Using the 3178 overlapping age-associated CpGs observed as significant (*p* \< 5 × 10^− 8^) among females in BEST, 2027(63.8%) (using bonferroni adjusted *p* \< 1.2 × 10^− 5^) were also significantly associated with age in HEALS. Likewise for males, among the 893 overlapping and significant (*p* \< 5 × 10^− 8^) age-associated CpGs observed in BEST, 572 (64.1%) (using bonferroni adjusted *p* \< 1.2 × 10^− 5^) were also significantly associated with age in HEALS. In the model adjusting for smoking status, the corresponding numbers and percentages among females were 1781/3294 or 54.1% and among males were 449/716 or 62.7%.

Additional file [6](#MOESM6){ref-type="media"} shows the beta values and *p*-values for the top 100 age-associated CpGs identified in BEST of which 68/91 (74.7%) among males and 81/91 (89.0%) among females are significantly associated with age in HEALS using a *p* \< 5 × 10^− 8^ while all overlapping CpGs are significant at *p* \< 0.05 among both sexes. Overlapping number of CpGs across additional sex stratified and sex adjusted models and significant sets can be observed in the Additional file [7](#MOESM7){ref-type="media"}a and b.

We examined associations with age for the 354 CpGs included in the Horvath methylation age predictor \[[@CR40]\] . The predicted age based on the calculator showed a strong correlation (r) with chronological age among both women (*r* = 0.89) and men (*r* = 0.81) (Fig. [2](#Fig2){ref-type="fig"}). While only 12 of our age-associated methylated loci among men and 44 among women were included in the 354 Horvath CpGs (Additional file [3](#MOESM3){ref-type="media"}), 140 of the Horvath CpG sites were differentially methylated among women in the expected direction (*p* \< 0.05), while 111 were differentially methylated among men (*p* \< 0.05 and expected direction). The median chronological age was younger for both sexes compared to the predicted methylation age and was 44 vs. 51.7 in males and 45 vs. 52.1 in females. Potential reasons for this discrepancy are mentioned in the discussion section. Fig. 2Correlation between chronological age and predicated age using Horvath \[[@CR40]\] identified age-related CpG markers among 211 women and 189 men. Colored lines in the plot represent loess lines of best fit and the black line represents perfect correlation

Characterization age-associated CpG sites with respect to genomic region {#Sec10}
------------------------------------------------------------------------

In order to determine if proximity to CpG islands was related to age-related differences in CpG methylation, we used categories defined by Illumina (i.e., island, shore, shelf, open sea) to estimate the proportion of age-associated CpGs that were hyper- vs. hypo-methylated within each category (Fig. [3](#Fig3){ref-type="fig"}). Across all CpGs, we observed a higher proportion of hyper-methylated vs. hypo-methylated sites, with a \> 2-fold difference for both sexes. This difference was largely driven by CpGs in island regions, which were almost exclusively hyper-methylated with increasing age, with \> 97% of CpGs showing hyper-methylation among both sexes. In contrast, in shelf and open sea regions, there were substantially more age-associated CpGs that were hypometylated with increasing age among both sexes (Fig. [3](#Fig3){ref-type="fig"}). Shore regions had a higher proportion of hyper-methylation among women, but higher proportion of hypo-methylation among men (Fisher exact test *p* = 0.0001). We also wanted to determine if age-associated CpGs were enriched in any of these categories. Compared to all CpG probes analyzed, age-associated CpG sites were strongly (all test *p* \< 1 x 10^− 11^) enriched in island regions and depleted in shelf and open sea regions (Fig. [4](#Fig4){ref-type="fig"}). Approximately two-fold enrichment/depletion was observed in these categories. We found evidence for slight enrichment in shore regions among women only (*p* = 3.8 x 10^-5^). Fig. 3a) Proportion of hyper-methylation vs. hypo-methylation among age-associated CpGs (*p* \< 5 x 10^− 8^) by genomic region, stratified by sex. b) Log2 odds ratio using the median unbiased estimate and the mid-p exact 95% confidence interval were used to compare women to men by genomic region in aggregate table format. All Fisher exact tests comparing the proportiontion of hyper-methylation (vs. hypo-methylation) within individual categories to \"all regions\" were significant among either men or women with all *p* \< 4.5 x 10^− 8^. For Fisher exact tests comparing the proportion of hyper-methylation (vs. hypomethlylation) between men and women within each category, only shore and open sea where significant with *p* = 0.0001 and 0.0342, respectively Fig. 4Proportion of CpGs residing in genomic regions defined by CpG density. All but the red bar represents age-associated CpGs. Fisher exact tests comparing enrichment/depletion within individual categories to all categories were significant (*p* \< 2 x 10^-11^) among men for island, shelf, and open sea regions and among women for all four categories (*p* = 3.8 x 10^-5^). Fisher exact tests comparing enrichment/depletion within categories between men and women were significant for island (*p* = 0.0071) and shore (*p* = 0.0015) regions

Characterization the top CpG sites for each sex in relationship to gene location {#Sec11}
--------------------------------------------------------------------------------

In order to determine if proximity to genes was related to methylation at age-related CpGs, we examined the proportion of hyper- vs. hypo-methylation at age-related CpGs within categories defined by Illumina (i.e., within 1500 basepairs (bp) of a transcription start site (TSS1500), within 200 bp of a TSS (TSS200), in a 5′ untranslated region (UTR), in the first exon, in the gene body, in the 3′ UTR, and Intergenic). In all categories, the proportion of age-associated CpGs that were hyper-methylated was greater than the hypo-methylated proportion (Fig. [5](#Fig5){ref-type="fig"}). This difference was most pronounced in the first exon and the TSS200 categories (*p* \< 0.0001 for both categories, in both sexes). The gene body category showed evidence of depleted for hyper-methylated sites in both sexes (*p* \< 0.005), when compared to all sites. Fig. 5a) Proportion of hyper-methylated and hypo-methylated CpGs among age-associated CpGs (*p* \< 5 x 10^− 8^) by relationship to gene category, stratified by sex. b) Log2 odds ratio using the median unbiased estimate and mid-p exact 95% confidence interval were used to compare women to men within each category in aggregate table format. Fisher exact tests comparing the proportion of hyper-methylation (vs. hypo-methylation) within individual categories to all categories were significant among men for TSS200 (*p* = 0.0001), first exon (*p* = 7.3 x 10^-11^), and body (*p* = 0.0001) regions and among women for TSS1500 (*p* = 1.2 x 10^-11^), TSS200 (*p* = 1.6 x 10^-9^), first exon (*p* = 2.2 x 10^-16^), and body (*p* = 0.0034) regions. For Fisher exact tests comparing hyper-methylation between men and women within each category, only body (*p* = 0.0125) was significant

We examined the proportions of age-associated CpGs in each category, and observed that enrichment/depletion compared to all 450 K CpGs varied across categories with the strongest enrichment occurring in the first exon category (*p* \< 5 x 10^-5^) and the strongest depletion occurring in the gene body category (*p* \< 0.0003) (Fig. [6](#Fig6){ref-type="fig"}). While the observed enrichment/depletion features appeared to be quite consistent across sexes, a slightly higher proportion of the age-associated CpGs were observed among men in the TSS200 (*p* = 0.0016) and first exon (*p* = 0.0419) locations. Fig. 6Proportion of age-associated CpGs residing in regions defined by gene features. The red bar represents all measured CpGs. Fisher exact tests comparing enrichment/depletion within individual categories to all categories were significant among men for first exon (*p* = 5.7 x 10^-6^) and body (*p* = 0.0002) regions and among women for TSS1500 (*p* = 0.0337), TSS200 (*p* = 3.5 x 10^-5^), 5′ UTR (*p* = 0.0307), first exon (*p* = 7.9 x 10^-5^), body (*p* = 0.0003), and intergenic (*p* = 0.0054). Fisher exact tests comparing enrichment/depletion within individual categories between men and women were significant for TSS200 (*p* = 0.0016) and first exon (*p* = 0.0419)

Expression of genes assigned to top 100 age-associated CpG sites {#Sec12}
----------------------------------------------------------------

In an attempt to understand the potential gene-regulatory implications of the top 100 (lowest *p*-values) age-associated CpGs within each sex, we estimated the association using a regression model between our top age-associated CpGs and expression values for the gene assigned (by Illumina) to each CpG along with all genes in the region +/− 200 basepairs around each CpG. Among the 100 top age-associated CpGs in each set, there were 417 CpG-gene associations tested among males and 538 associations tested among females. Among the 417 in the male set, we observed 3 significant (*p* \< 0.0001) associations between methylation and expression; 2 of these (66%) were inverse associations. Among the 538 in the female set, 11 showed significant associations (*p* \< 0.00009), and 8(73%) were inverse. Based on these significant associations, we looked for evidence that a CpG-expression relationship varied with age by adding an age interaction term to the regression model which may suggest there are functional changes to the way the CpG and gene expression associate with age. We observed 1/3 significant interactions with age among males and 3/11 among females and show the age-gene expression and CpG-gene expression plots with sex-specific correlations (Fig. [7](#Fig7){ref-type="fig"}). These CpG-gene sets are listed in Additional file [8](#MOESM8){ref-type="media"} along with genomic region. Fig. 7Scatterplots of CpG beta values and the expression of its Illumina-assigned gene (right-hand side) and scatterplots of the expression of the same Illumina-assigned gene by age (left side). CpGs and gene pairs were chosen based on significant age interactions within the regression model. All plots distinguish points as female (salmon color) or male (blue color) and include a linear line of best fit for each sex

Discussion {#Sec13}
==========

In this study of the relationship between age and genome-wide DNA methylation patterns in whole blood samples collected from a Bangladeshi population, we observed differentially methylated CpGs with respect to age across the entire genome. More age-associated CpGs were observed among women compared to men, but the presence of association with age was consistent across sexes for most age-associated CpGs and the amount of overlap in top CpG remained relatively consistent regardless of the regression model and confounders included. There was a strong correlation between chronological age and the Horvath methylation age prediction model \[[@CR40]\] among both sexes. However, we observed limited overlap between the most significant (*p* \< 5 x 10^−8^) age-associated CpGs identified in this work and the CpGs used in the Horvath calculator which is expected as explained in a recent review \[[@CR51]\]. Alternative explanations include that there are differences in epigenetic aging features due to tissue type and/or population between our data and the data used to train existing DNA methylation aging models.

We observed similar enrichment in genomic features for age-associated CpGs between sexes. When comparing all CpGs to age-associated CpGs, islands were strongly enriched for age-associated sites, with weaker enrichment for age-associated CpGs in shore regions. Age-associated CpGs were depleted in shelf and open sea regions. We observed enrichment for age-associated CpGs in intergenic regions, with general depletion in gene regions.

Among age-associated CpGs, islands contained sites that were almost exclusively hyper-methylated with increasing age, while shelf and open sea regions contained more hypo- as compared to hyper-methylated sites. Among all age-associated CpGs on the 450 K array, hyper-methylation was approximately twice as common as hypo-methylation, and enrichment for hyper-methylated sites was present in all categories defined according to proximity to gene/TSS. The observation that age-associated hyper-methylation tends to occur in islands and promoter regions \[[@CR52]\] while hypo-methylation tends to occur in shelf, shore, and open sea regions is consistent with previous literature \[[@CR53]\]. The observed enrichment of age-associated CpGs in island regions (with depletion in open sea and body regions) is also consistent with previous literature \[[@CR53]\].

Sex differences in methylation patterns have been observed in studies of both newborns and adults and in different tissue types (e.g., blood and saliva) \[[@CR54]--[@CR60]\]. During preimplantation embryo development, the demethylation process is much faster in males than in females \[[@CR61]\], and several prior studies have demonstrated that most age-associated CpG sites showed a higher methylation in females compared to males \[[@CR9], [@CR32], [@CR62], [@CR63]\]; however, our results based on our top 100 age-associated CpGs do not support this conclusion (data not shown).

To our knowledge, there are no genome-wide epidemiologic studies that have characterized the association between age and DNA methylation in blood among males and females separately. There are at least 5 studies which specifically investigated sex-specific methylation changes with age. However, these studies, have focused on specific genome locations or were conducted within other tissue types \[[@CR64]--[@CR67]\]. Sex-based differences in the epigenetic aging process could be related to the observation that females and males have different rates of disease incidence for many age-related diseases and different risk thresholds for susceptibility factors to those diseases.

Some of the specific age-associated CpGs identified using blood within the current study are likely to be observed when evaluated in other tissues, however, important considerations include the tissue type and all samples coming from same individuals. A recent paper by Zhu et al. 2018 \[[@CR68]\], evaluated age-associated DNA methylation from multiple large publicly available datasets and were able to conduct sub-analyses using methylation across different tissues from the same set of individuals. These authors demonstrated that many age-associated methylation sites are shared across tissue types (as much as 70% or more), however, the pattern is dependent on the specific CpG site and the specific tissues that are being compared \[[@CR68]\]. They highlight matching on individual is a key condition when looking at age-related methylation across tissues. Future studies should assess the tissue-independence of our results using methylation data from studies of diverse tissues types obtained from multi-tissue donors, such as the Genotype-Tissue Expression (GTEx) project \[[@CR69]\].

The association between increasing methylation in promoter regions and decreasing corresponding gene expression levels has been widely observed in blood, and is believed to reflect epigenetic silencing of promoters \[[@CR30], [@CR53], [@CR70]\]. Likewise, a negative association between gene expression and gene body methylation has been demonstrated in blood of various populations \[[@CR71], [@CR72]\], but the functional importance of non-promoter region methylation associations with expression are not well understood. Hypothesized mechanisms including modulation of chromatin structure, regulation of alternative promoters, or nucleosome positioning. In an attempt to understand the potential gene-regulatory roles of our top 100 age-associated CpGs within each sex, we examined those CpGs that were assigned to a gene and observed a significant association with expression in 3/417 in the male set and 11/538 in the female set. Thus, the potential regulatory roles for the vast majority of these age-associated CpGs are unclear since they generally are not associated with expression which has been observed with other age-related CpGs \[[@CR51]\]. However, these CpGs still tend to occur in promoter regions (TSS1500 or TSS200) (Additional file [4](#MOESM4){ref-type="media"}) and a potential difference in age-related variably methylated positions (aVMPs) in males compared to females may explain why we have observed a higher number of CpG sites correlated with gene expression compared with previous studies \[[@CR53]\], but, none of our top 100 age-associated CpG sites were contained in that list \[[@CR73]\]. Of the 276 CpGs determined to be different based on sex at birth \[[@CR65]\] using a *p* of 5 × 10^--8^ (like in our paper), we find that only 2 CpGs are significantly associated with age in our model which adjusted for sex and smoking, but in the same model we observe that methylation for 180 out of these 276 are significantly different based on the sex *p*-value. The regression coefficient for age ranges from − 0.197 to 0.143 (not shown).

Age prediction models using methylation at CpGs (i.e., epigenetic clock or biological aging) have been shown to predict aging-related outcomes, such as all-cause mortality \[[@CR43]\], cognitive and physical functions \[[@CR42]\], Down syndrome \[[@CR74]\], and cancers of the lung, breast, kidney, and blood \[[@CR75]\]. These studies demonstrate that a surrogate tissue (blood) is useful for detecting accelerated aging effects that predispose to aging-related diseases of other tissues and that implementation of screening and subsequent early diagnosis could help improve the effectiveness of targeted interventions and prognoses for at-risk populations \[[@CR51]\]. There is also the potential for risk assessment in an individual's family members by investigating key disease-associated methylation markers that demonstrate similar features inter-generationally \[[@CR76], [@CR77]\]. However, this research is complex and at a very early stage \[[@CR78]\]. Poor correlation has been observed between epigenetic clock predictors (Hannum \[[@CR38]\] or Horvath \[[@CR40]\] methylation age) and telomere length, however, both have been observed to have significant independent associations with age and mortality \[[@CR79]\]. This suggests different pathways/mechanisms are being represented by telomere and DNA methylation markers \[[@CR79]\]. Developing methods to combine information from these and other biomarkers of biological aging could provide predictions regarding which patients to target for interventions to improve overall quality of life and survival.

All epigenome-wide associations studies need to consider adjustment for cell type composition. When DNA methylation is assessed in whole blood we need to adjust for leukocyte subtypes, which are known to be heterogeneous with respect to methylation patterns \[[@CR59], [@CR60]\]. Different proportions of blood cell types exist between females and males; therefore, addressing cell-type proportions related to sex impacts the number of significant CpGs observed \[[@CR62], [@CR80]\]. Therefore, we utilized a statistical method to infer cell type fractions in our samples; the assumptions of the statistical method have been described elsewhere \[[@CR81], [@CR82]\]. There were two methods we considered. The first is MethylSectrum \[[@CR48]\], which estimates cellular proportions using a reference data set of cell-type specific DNA methylation. The second method, and the primary method used in our work, is a reference-free method \[[@CR47]\] that estimates latent variables (including cell type composition factors) using a statistical formula based on an empirical test of the variance explained; hence, this method is not restricted to estimation of only 6 cell-types and can capture additional variables such as experimental batch. In our study, we observed a pattern of asymmetry (much larger number of significant beta values above 0 compared to below 0) while using the MethylSectrum method which was not observed when using the reference-free method. This observation may suggest that the estimates produced by the reference-based MethylSpectrum method, often used in other studies \[[@CR48], [@CR57]\] could be affected by unmeasured confounders, and the reference data used may not be ideal for all population world-wide.

There are several reasons we may have observed a larger number of significant age-associated CpGs among females compared to males. There was a larger sample of females compared with males which means there is a power difference between the sex-stratified analyses. The age distribution is more variable (i.e., wider range of ages) among females potentially contributing to the small *p*-values observed among females. There were many more males who were current or former smokers compared with females, thus an additional analysis adjusting for smoking was conducted and is included in the additional files.

Strengths of this study include the relatively large sample size and the availability of genome-wide DNA methylation and expression data from a population-based sample. In addition, very few studies of DNA methylation have been conducted in South Asian individuals. While previous studies have demonstrated associations between age and DNA methylation markers, we were also able to evaluate expression of genes residing near our age-associated CpG sites.

Conclusions {#Sec14}
===========

Our results suggest a similar feature of age-associated CpGs across the genome for males and females. Consistent with prior studies, age-associated CpG sites residing in island and promoter regions tend to be hyper-methylated with increasing age, while age-related CpGs residing in shelf and open sea, regions tend to be hypo-methylated with increasing age. Enrichment of age-associated CpGs occurs in island regions while depletion of age-associated CpGs is observed in open sea, shelf, and gene body regions. Additional studies need to confirm the associations observed in this study and assess potential differences across populations. Future work utilizing multiple epigenetic datasets will likely lead to an enhanced understanding of the role epigenetic factors play in the development of age-associated diseases. In addition, utilizing methylation-based age-prediction models (i.e., biological age) may allow a more accurate categorization of individual disease-specific risks compared with the traditional use of chronological age.

Additional files
================

 {#Sec15}

Additional file 1:Age distribution for males and females in BEST. (PDF 55 kb) Additional file 2:Top 50 results based on *p*-value for analysis methods Methylspectrum and RefFreeEWAS. (PDF 244 kb) Additional file 3:Number of top 100 age-associated CpGs in common between analysis methdos Methylspectrum and RefFreeEWAS. (PDF 222 kb) Additional file 4:Number of top 100 age-associated CpGs in common between different RefFreeEWAS models. (PDF 72 kb) Additional file 5:Age distribution for males and females in HEALS. (PDF 56 kb) Additional file 6:Top 100 results across BEST (original) and HEALS (validation) datasets based on top age-associated CpGs observed in BEST. (PDF 69 kb) Additional file 7:Number of top 91 age-associated CpGs in common between different RefFreeEWAS models using original dataset and a) top 100 age-associated CpGs in Validation dataset or b) significant (\< 5e-8) age-associated CpGs in the Validation dataset (PDF 69 kb) Additional file 8:UCSC genome location information for a subset of the top 100 age-associated CpGs observed to be significantly associated with its Illumina assigned gene expression (PDF 112 kb)

aVMPs

:   Age-related variably methylated positions

BEST

:   Bangladesh Vitamin E and Selenium Trial

bp

:   basepairs

CD4T)

:   T-helper

CpG

:   5'---C---phosphate---G---3'

DNA

:   Deoxyribonucleic acid

Gran

:   Granulocytes

GTEx

:   Genotype-Tissue Expression

HEALS

:   Health Effects of Arsenic Longitudinal Study

Mono

:   Monocytes

NK

:   Natural killer

r

:   correlation

RNA

:   Ribonucleic acid

SD

:   Standard deviation

SEs

:   Standard errors

TSS

:   Transcription start site

UTR

:   Untranslated region

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Thank you to the BEST study participants and to the study staff and personnel who made this analysis possible.

RJJ: made substantial contributions to the analysis and interpretation of the data; LT: made substantial contributions to the analysis and interpretation of the data, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft; MA: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; FJ: involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; MR-Z: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; GS: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; MTI: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; HS: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; TI: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; MR: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; MY: made substantial contributions to the conception and design, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; MGK: supervised the entire lab work to generate the data, primary analysis of processing the entire raw image data to generate the beta-values, the QC and acquisition of data, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; JAB: made substantial contributions to the conception and design and acquisition of data, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; HA: made substantial contributions to the conception and design and acquisition of data, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work; BLP: made substantial contributions to the conception and design and acquisition of data and analysis and interpretation of the data, involved in drafting the manuscript or revising it critically for important intellectual content, gave final approval of published draft and agreed to be accountable for all aspects of work. All authors read and approved the final manuscript.

Partial funding support to analyze and interpret the data and write the manuscript for RJJ came from North Dakota State University COBRE Biostatistics Core Facility (Grant: P20GM109024). The BEST study data collection was funded through grant R01CA107431 (HA). RJJ, HA and BLP were supported through grants R01ES020506, R35ES028379, P30CA014599, and P30ES027792 to analyze and interpret the data and write the manuscript.

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

The study's processes and procedures, including participants' written informed consent, were reviewed, monitored, and approved by the University of Chicago's IRB.

Not applicable.

The authors declare that they have no competing interests.
